STREAMLINE ($NASDAQ:STRM): Additionally, the company’s net income was reported at USD -2.5 million on September 14, 2023, representing a decrease of -0.8 million from the prior year.
Analysis – STRM Intrinsic Value Calculation
GoodWhale’s analysis of STREAMLINE HEALTH SOLUTIONS reveals that its fair value is estimated to be around $1.7 per share. This figure was determined using GoodWhale’s proprietary Valuation Line which takes into account factors such as earnings, growth rates, and market data. Currently, STREAMLINE HEALTH SOLUTIONS stock is traded at $0.9, which is a 48.0% discount to its fair value. This could indicate that the stock is currently undervalued and could be a good buy for savvy investors. More…
Risk Rating Analysis
Star Chart Analysis
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for STRM. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for STRM. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for STRM. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for STRM are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
It offers solutions in the areas of integrated patient data, workflow management, analytics, and performance improvement. Streamline Health Solutions Inc faces competition from CareCloud Inc, iCoreConnect Inc, and Dialogue Health Technologies Inc, which are all healthcare technology firms that offer similar solutions to Streamline Health Solutions Inc.
CareCloud Inc is a healthcare technology company that provides an integrated suite of cloud-based practice management, revenue cycle, and patient engagement solutions to health systems, physicians, and other healthcare providers. With a market cap of 50.68M as of 2023, the company is well-positioned for growth in the coming years. CareCloud’s Return on Equity (ROE) of 3.68% illustrates that their investors have seen a good return on their investments. The company is continuing to focus on improving their business operations to drive additional value for their shareholders.
iCoreConnect Inc is a healthcare technology company focused on providing innovative, secure and compliant communication solutions to healthcare organizations. Its market cap of 24.14M as of 2023 reflects its strong financial performance and growth prospects. Its Return on Equity (ROE) of 149.87% indicates its strong profitability, with the company reinvesting most of its income back into the business to drive further growth. iCoreConnect Inc’s products are designed to improve the communication, efficiency, and security of healthcare practice operations by providing cloud-based solutions such as secure texting, HIPAA-compliant email, and patient portals. The company also offers a suite of products that enable healthcare providers to streamline their practice operations and improve their patient care.
– Dialogue Health Technologies Inc ($TSX:CARE)
Founded in 2011, Dialogue Health Technologies Inc is a health technology company that designs, develops, and distributes AI-enabled healthcare solutions. With a market cap of 228.91M as of 2023, the company has seen an impressive growth over the years. However, its Return on Equity of -15.61% is a major indicator of the strength of its financial performance. ROE is an important indicator of a company’s profitability and is often used to compare the efficiency of different companies. Dialogue’s negative ROE shows that the company’s profits are not sufficient to compensate its shareholders, indicating that there may be issues with management or strategic decisions.
Investors in Streamline Health Solutions may have reacted negatively to the company’s financial results released on September 14 2023, which showed a total revenue of USD 5.8 million for the end of FY2024 Q2 on July 31 2023, a 3.7% decrease from the same period in the previous year. Net income was also reported at USD -2.5 million, a decrease of -0.8 million from the prior year. This led to the stock price moving down on the same day, indicating investor confidence in the company’s current performance and outlook.